Merz researches, develops, produces and distributes innovative pharmaceutical products in the areas of neurology and psychiatry as well as in clinical and aesthetic dermatology. In the area of Alzheimer’s research, the company has achieved a leading position with the first active ingredient worldwide for the treatment of moderate to severe stages of Alzheimer’s disease. Memantine is the second-best selling Alzheimer drug worldwide. In addition to the pharmaceutical market, Merz also operates in the health sector beyond the scope of pharmacies. With its established tetesept® and Merz Spezial® brands, Merz Consumer Care is one of the leading suppliers of self-medication products, dietary supplements, and skin care products in the German-speaking countries. The Merz Pharma Group employs 1,745 people worldwide (prior year: 1,619). The Company generated revenue of EUR 589.8 million in the fiscal year 2008/09 (prior year: EUR 546.5 million).
- Neurology
- Psychiatry
- Clinical and aesthetic dermatology
- Self-medication and dietary supplements (tetesept®)
- Skin care (Merz Spezial®)
- contact@merz.de
- www.merz.de
- T: +49 (0)69 150 30
- F: +49 (0)69 150 32 00